Perubahan Enzim Transaminase Paska Pemberian Terapi Antiretroviral pada Pasien Infeksi Human Immunodeficiency Virus
Main Article Content
Abstract
Antiretroviral therapy has been shown to reduce mortality in Human Immunodeficiency Virus-infected patients. However, this treatment is hepatotoxic particularly combination therapies, as the liver is the target organ for the metabolism of substrates used in antiretroviral therapy. This study aims to determine the changes in transaminase levels after antiretroviral therapy in these patients. This study was using prospective cohort, is conducted in 62 patients. The mean AST level was significantly higher 3 months after treatment than before (49.1 U/L vs. 47.9 U/L; p < 0.05), representing a 2.5% increase. The mean ALT level was significantly lower 3 months after treatment (37.5 U/L vs. 51.0 U/L; p < 0.05). The total lymphocyte count was significantly correlated with changes in ALT levels. In patients infected with the human immunodeficiency virus (HIV) and receiving combination antiretroviral therapy, a decrease in ALT levels and an increase in AST levels are observed; therefore, it is necessary to monitor transaminase enzymes regularly.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Abubakar MG, Abduljalil MM, Nasiru YI. Changes in Liver Function Enzymes of HIV/AIDS Patients Treated with Antiretroviral Drugs (ARVS) in Specialist Hospital, Sokoto, Nigeria. Niger J Basic Appl Sci. 2014;22(3):85–89.
Achondou AE, Atanga R, Tanlaka EJ, et al. Variation of Serum Transaminases in HIV/AIDS Patients on Different Antiretroviral Regimens, Attending the Saint Elizabeth Hospital, Shisong, Northwest Region, Cameroon. 2017;6(1):6–10.
Deshwal R, Arora S. Serum alanine aminotransferase elevations in HIV positive patients on antiretroviral therapy in India. J Assoc Physicians India. 2019;67(March):67–70.
Gebremicael G, Tola HH, Gebreegziaxier A, et al. Incidence of hepatotoxicity and factors associated during highly active antiretroviral therapy in people living with hiv in ethiopia: A prospective cohort study. HIV/AIDS - Res Palliat Care. 2021;13:329–336.
Giannini EG, Testa R, Savarino V. Liver enzyme alteration: A guide for clinicians. Cmaj. 2005;172(3):367–379.
Kemenkes RI. Infodatin Pusat Data dan Informasi Kementerian Kesehatan RI. Published online 2017:1–12.
Mataranyika PA, Kibuule D, Kalemeera F, et al. Liver enzyme elevations in a cohort of HIV/AIDS patients on first-line antiretroviral therapy in Namibia: Findings and implications. Alexandria J Med. 2018;54(1):49–56.
Osakunor DNM, Obirikorang C, Fianu V, Asare I, Dakorah M. Hepatic enzyme alterations in HIV patients on antiretroviral therapy: A case-control study in a hospital setting in Ghana. PLoS One. 2015;10(8):1–10.
Page M, Taylor S. Antiretroviral pharmacology. Med (United Kingdom). 2018;46(5):287–292.
Tadesse BT, Foster BA, Kabeta A, et al. Hepatic and renal toxicity and associated factors among HIV-infected children on antiretroviral therapy: a prospective cohort study. HIV Med. 2019;20(2):147–156.
UNAIDS. UNAIDS fact sheet - Latest statistics on the status of the AIDS epidemic. End Aids Epidermics. 2020:1-8.
WHO. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV: Early Release. Guidel when to start Antiretrovir Ther pre-exposure Prophyl HIV Early Release. 2016;2(2). doi:10.1097/00022744-199706000-00003